Quoting Nic Marais <[log in to unmask]>:

> Isn't that what Eldepryl was also supposed to do?
> 
> I feel like a Pawn....
> 
> Nic 56,14
> 
> On Mon, Jun 16, 2008 at 8:21 PM, rayilynlee <[log in to unmask]> wrote:
> 
> > Teva, Lundbeck say Azilect slows Parkinson's
> >
> > Reuters - 41 minutes ago
> > TEL AVIV/STOCKHOLM, June 16 - Teva Pharmaceutical Industries Ltd revealed
> > positive results on Monday for its Azilect Parkinson's treatment, boosting
> > its shares and those of Danish partner Lundbeck .
> > Tel Aviv-traded shares in Teva jumped 3.2 percent while Lundbeck was up
> 3.7
> > percent at 1336 GMT.
> > Teva, the world's biggest maker of generic drugs, said it intends to
> submit
> > these results to the regulatory authorities in the United States and
> Europe.
> > It said the 1 mg tablets of its Azilect drug slowed the progression of
> > Parkinson's disease in a Phase III trial. It promotes the drug with
> Lundbeck
> > in the three major European markets: Britain, Germany and France.
> > Teva and Lundbeck said 1 mg tablets of Azilect met all three primary end
> > points in the trial, as well as the secondary and additional end points,
> all
> > with statistical significance.
> > The study also confirmed the safety and tolerability of Azilect and based
> > on these results, Azilect could become the first Parkinson's disease
> > treatment to receive an indication for slowing the progress of the
> disease,
> > the companies said.
> > "These positive results could dramatically increase the market potential
> > for Azilect, allowing Azilect to join Copaxone as another major Teva drug
> > for neurological disorders," Shlomo Yanai, president and chief executive
> of
> > Teva, said in a statement.
> > Teva's Copaxone became the No. 1 global treatment for multiple sclerosis
> in
> > the first quarter.
> > "Azilect, an innovative drug that was not very significant, becomes a drug
> > with the potential to be a blockbuster," said Gal Reiter, an analyst at
> > Israeli brokerage Clal Finance.
> > SALES TO JUMP
> > Global sales of Azilect rose 50 percent in the first quarter from a year
> > earlier to $37.5 million. It sales were $120 million in 2007.
> > "If in the past we estimated the potential sales of the drug at $300
> > million, now we estimate that the potential has at least doubled," Reiter
> > said.
> > "However, it will take time until Azilect's impact becomes substantial."
> > The analyst noted that while Azilect's patent runs until 2012, this
> > clinical trial could enable an extension until 2017.
> > Bank Hapoalim analyst Gilad Sarig estimated Azilect's potential sales at
> $1
> > billion.
> > "It is expected to become the leading drug in the Parkinson's market
> within
> > a few years," he said in a research note, adding he is not changing his
> > forecasts for the company until the timetable with the FDA becomes clear.
> > The study protocol was based on the recommendations and guidance of the
> > U.S. Food and Drug Administration. The 18-month study, the first of its
> > kind, is one of the largest conducted in Parkinson's disease, involving
> > 1,176 patients with early Parkinson's disease in 14 countries and 129
> > medical centres.
> > Teva also said the 2 mg dose in the study met two of the three primary end
> > points as well as the secondary end point. It was also found to be safe
> and
> > well tolerated.
> > Rayilyn Brown
> > Director AZNPF
> > Arizona Chapter National Parkinson Foundation
> > [log in to unmask]
> > ----------------------------------------------------------------------
> > To sign-off Parkinsn send a message to: mailto:
> > [log in to unmask]
> > In the body of the message put: signoff parkinsn
> >
> 
> ----------------------------------------------------------------------
> To sign-off Parkinsn send a message to: mailto:[log in to unmask]
> In the body of the message put: signoff parkinsn
> 




----------------------------------------------
This mail sent through http://www.ukonline.net

----------------------------------------------------------------------
To sign-off Parkinsn send a message to: mailto:[log in to unmask]
In the body of the message put: signoff parkinsn